Welcome to LookChem.com Sign In|Join Free
  • or
Ethyl 2-bromo-3-methylbutyrate, also known as Ethyl 2-Bromoisovalerate (CAS# 609-12-1), is an organic compound with a clear colorless liquid appearance. It is primarily utilized in the field of organic synthesis due to its unique chemical properties.

609-12-1

Post Buying Request

609-12-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

609-12-1 Usage

Uses

Used in Organic Synthesis:
Ethyl 2-bromo-3-methylbutyrate is used as a synthetic intermediate for the production of various organic compounds. Its chemical structure allows it to be a versatile building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Ethyl 2-bromo-3-methylbutyrate is used as a key component in the development of new drugs. Its unique chemical properties make it a valuable asset in the synthesis of novel therapeutic agents.
Used in Agrochemical Industry:
Ethyl 2-bromo-3-methylbutyrate is also employed in the agrochemical industry for the synthesis of new pesticides and other agricultural chemicals, contributing to the development of more effective and environmentally friendly products.
Used in Specialty Chemicals:
In the specialty chemicals sector, Ethyl 2-bromo-3-methylbutyrate is used as a raw material for the production of various compounds with specific applications, such as fragrances, dyes, and additives for the plastics and coatings industries.

Check Digit Verification of cas no

The CAS Registry Mumber 609-12-1 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 6,0 and 9 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 609-12:
(5*6)+(4*0)+(3*9)+(2*1)+(1*2)=61
61 % 10 = 1
So 609-12-1 is a valid CAS Registry Number.
InChI:InChI=1/C7H13BrO2/c1-4-10-7(9)6(8)5(2)3/h5-6H,4H2,1-3H3/t6-/m0/s1

609-12-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (B22525)  Ethyl 2-bromoisovalerate, 97%   

  • 609-12-1

  • 5g

  • 545.0CNY

  • Detail
  • Alfa Aesar

  • (B22525)  Ethyl 2-bromoisovalerate, 97%   

  • 609-12-1

  • 25g

  • 2084.0CNY

  • Detail

609-12-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name Ethyl 2-Bromoisovalerate

1.2 Other means of identification

Product number -
Other names Butanoic acid, 2-bromo-3-methyl-, ethyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:609-12-1 SDS

609-12-1Synthetic route

ethanol
64-17-5

ethanol

2-bromoisovaleric acid
10323-40-7, 565-74-2

2-bromoisovaleric acid

ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

Conditions
ConditionsYield
With sulfuric acid for 16h; Reflux;92%
With sulfuric acid for 2h; Heating;81%
With sulfuric acid In benzene for 48h; Heating;80%
With sulfuric acid for 36h; Heating / reflux;55%
With sulfuric acid
2-bromo-3-methyl-butyryl bromide
26464-05-1

2-bromo-3-methyl-butyryl bromide

ethanol
64-17-5

ethanol

ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

Conditions
ConditionsYield
at 60℃; for 1h;62%
at 80℃;
3-methylbutyric acid
503-74-2

3-methylbutyric acid

ethanol
64-17-5

ethanol

ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

Conditions
ConditionsYield
(i) SOCl2, (ii) Br2, I2, (iii) /BRN= 1718733/; Multistep reaction;
(i) SOCl2, (ii) Br2, (iii) /BRN= 1718733/; Multistep reaction;
Ethyl isovalerate
108-64-5

Ethyl isovalerate

ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

Conditions
ConditionsYield
(i) cyclohexyl-isopropyl-amine <li salt="">, THF, (ii) Br2</li>; Multistep reaction;
potassium salt of isopropylmalonic acid monoethyl ester

potassium salt of isopropylmalonic acid monoethyl ester

ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

Conditions
ConditionsYield
With tetrachloromethane; bromine Destillation des Reaktionsprodukts unter vermindertem Druck;
tetrachloromethane
56-23-5

tetrachloromethane

bromine
7726-95-6

bromine

potassium 2-(ethoxycarbonyl)-3-methylbutanoate

potassium 2-(ethoxycarbonyl)-3-methylbutanoate

ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

Conditions
ConditionsYield
Destillieren des Reaktionsprodukts unter vermindertem Druck;
1,1-Dichloro-3-methyl-1-butene
32363-91-0

1,1-Dichloro-3-methyl-1-butene

ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

Conditions
ConditionsYield
With methanesulfonic acid; bromine; chlorine In ethanol
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

phenylacetonitrile
140-29-4

phenylacetonitrile

ethyl 2-isopropyl-3-oxo-4-phenylbutanoate
176519-53-2

ethyl 2-isopropyl-3-oxo-4-phenylbutanoate

Conditions
ConditionsYield
Stage #1: ethyl 2-bromoisovalerate With zinc In tetrahydrofuran for 0.166667h; Reflux;
Stage #2: phenylacetonitrile In tetrahydrofuran for 0.5h; Reflux;
100%
With zinc In tetrahydrofuran for 0.166667h; Heating;92%
With iodine; zinc In tetrahydrofuran Inert atmosphere;90%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

3,5-dimethylphenylacetonitrile
39101-54-7

3,5-dimethylphenylacetonitrile

ethyl 4-(3,5-dimethylphenyl)-2-isopropyl-3-oxobutanoate
210645-97-9

ethyl 4-(3,5-dimethylphenyl)-2-isopropyl-3-oxobutanoate

Conditions
ConditionsYield
Stage #1: ethyl 2-bromoisovalerate With zinc In tetrahydrofuran for 0.166667h; Reflux;
Stage #2: 3,5-dimethylphenylacetonitrile In tetrahydrofuran for 0.5h; Reflux;
100%
Stage #1: ethyl 2-bromoisovalerate; 3,5-dimethylphenylacetonitrile With zinc In tetrahydrofuran for 1h; Heating / reflux;
Stage #2: With potassium carbonate In water for 0.75h;
Stage #3: With hydrogenchloride In water for 0.75h;
52%
With hydrogenchloride; zinc 1.) THF; Multistep reaction;
Stage #1: ethyl 2-bromoisovalerate; 3,5-dimethylphenylacetonitrile With iodine; zinc In tetrahydrofuran for 0.5h; Addition; reduction; Heating;
Stage #2: With potassium carbonate In tetrahydrofuran at 20℃; for 0.5h; Hydrolysis;
Stage #3: With hydrogenchloride In tetrahydrofuran at 20℃; for 0.5h; Hydrolysis;
Stage #1: ethyl 2-bromoisovalerate; 3,5-dimethylphenylacetonitrile With zinc In tetrahydrofuran
Stage #2: With hydrogenchloride
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

4-Methoxybenzenethiol
696-63-9

4-Methoxybenzenethiol

2-(4-methoxy-phenylsulfanyl)-3-methyl-butyric acid ethyl ester
212768-71-3

2-(4-methoxy-phenylsulfanyl)-3-methyl-butyric acid ethyl ester

Conditions
ConditionsYield
With potassium carbonate In acetone for 8h; Heating;99%
99%
99%
99%
99%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

4-sulfanylphenol
637-89-8

4-sulfanylphenol

ethyl isopropyl [4-(hydroxyphenyl)sulfanyl]acetate
287393-36-6

ethyl isopropyl [4-(hydroxyphenyl)sulfanyl]acetate

Conditions
ConditionsYield
99%
With triethylamine In chloroform at 20℃;
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

4-Methoxybenzenethiol
696-63-9

4-Methoxybenzenethiol

2-(4-methoxy-phenylsulfanyl)-3-methyl-butyric acid ethyl ester
212768-71-3

2-(4-methoxy-phenylsulfanyl)-3-methyl-butyric acid ethyl ester

N-hydroxy-2-(4-methoxy-phenylsulfanyl)-3-methyl-butyramide

N-hydroxy-2-(4-methoxy-phenylsulfanyl)-3-methyl-butyramide

Conditions
ConditionsYield
99%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

benzenesulfonamide
98-10-2

benzenesulfonamide

2-bromo-3-methyl-N-(phenylsulfonyl)butanamide

2-bromo-3-methyl-N-(phenylsulfonyl)butanamide

Conditions
ConditionsYield
Stage #1: ethyl 2-bromoisovalerate; benzenesulfonamide In toluene at 50℃; for 0.166667h; Sealed tube;
Stage #2: With titanium tetrachloride In toluene at 115℃; for 8h; Solvent; Reagent/catalyst; Sealed tube;
98%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

3,5-dimethoxyphenylacetonitrile
13388-75-5

3,5-dimethoxyphenylacetonitrile

ethyl 4-(3,5-dimethoxyphenyl)-2-isopropyl-3-oxobutyrate

ethyl 4-(3,5-dimethoxyphenyl)-2-isopropyl-3-oxobutyrate

Conditions
ConditionsYield
Stage #1: ethyl 2-bromoisovalerate With zinc In tetrahydrofuran for 0.166667h; Reflux;
Stage #2: 3,5-dimethoxyphenylacetonitrile In tetrahydrofuran for 0.5h; Reflux;
94%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

2-iodo-3-methyl-butyric acid ethyl ester
33666-91-0

2-iodo-3-methyl-butyric acid ethyl ester

Conditions
ConditionsYield
With sodium iodide In acetone Heating / reflux;93%
With sodium iodide In acetone Heating / reflux;93%
With sodium iodide In acetone Heating / reflux;93%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

pyrazole-4-boronic acid pinacol ester
269410-08-4

pyrazole-4-boronic acid pinacol ester

ethyl 3-methyl-2-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]butanoate

ethyl 3-methyl-2-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]butanoate

Conditions
ConditionsYield
With caesium carbonate In N,N-dimethyl-formamide at 90℃; for 12h;93%
With caesium carbonate In acetonitrile for 4h; Reflux;79%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

1-(2-hydroxy-4-methoxyphenyl)ethanone
552-41-0

1-(2-hydroxy-4-methoxyphenyl)ethanone

2-(2-Acetyl-5-methoxy-phenoxy)-3-methyl-butyric acid ethyl ester
176642-59-4

2-(2-Acetyl-5-methoxy-phenoxy)-3-methyl-butyric acid ethyl ester

Conditions
ConditionsYield
With potassium carbonate In dimethyl sulfoxide Ambient temperature;91%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

ethyl 2,2-dibromo-3-methylbutanoate
404392-16-1

ethyl 2,2-dibromo-3-methylbutanoate

Conditions
ConditionsYield
Stage #1: ethyl 2-bromoisovalerate With lithium diisopropyl amide In tetrahydrofuran; hexane at -78℃; for 0.5h;
Stage #2: With 1,2-dibromo-1,1,2,2-tetrafluoroethane In tetrahydrofuran; hexane at -78℃; for 0.5h;
91%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

4-bromobenzyl mercaptan
19552-10-4

4-bromobenzyl mercaptan

(4-bromophen-yl-4-methylsulfanyl)-3-methylbutanoic acid ethyl ester
796739-75-8

(4-bromophen-yl-4-methylsulfanyl)-3-methylbutanoic acid ethyl ester

Conditions
ConditionsYield
With potassium carbonate In DMF (N,N-dimethyl-formamide) at 0℃; for 2h;90%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

3,4-dihydronaphthalene-1(2H)-one
529-34-0

3,4-dihydronaphthalene-1(2H)-one

2-(3,4-Dihydro-naphthalen-1-yl)-3-methyl-butyric acid ethyl ester
143837-09-6

2-(3,4-Dihydro-naphthalen-1-yl)-3-methyl-butyric acid ethyl ester

Conditions
ConditionsYield
With zinc89%
With hydrogen cation; zinc82%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

4-fluorophenylacetonitrile
459-22-3

4-fluorophenylacetonitrile

ethyl 4-(4-fluorophenyl)-2-isopropyl-3-oxobutanoate
1254831-88-3

ethyl 4-(4-fluorophenyl)-2-isopropyl-3-oxobutanoate

Conditions
ConditionsYield
With iodine; zinc In tetrahydrofuran Inert atmosphere;89%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

naphthalen-2-ylamine
91-59-8

naphthalen-2-ylamine

(RS)-ethyl α-N-(2-naphthyl)valinate
99631-76-2

(RS)-ethyl α-N-(2-naphthyl)valinate

Conditions
ConditionsYield
With sodium carbonate at 140℃; for 2h;88%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

Hexanethiol
111-31-9

Hexanethiol

ethyl 2-hexylsulfanyl-3-methyl-butanoate
1137737-29-1

ethyl 2-hexylsulfanyl-3-methyl-butanoate

Conditions
ConditionsYield
With potassium carbonate In acetone for 4h; Reflux;88%
2-(2-methyl-1,3-dioxolane-2-yl)ethan-1-amine
62240-37-3

2-(2-methyl-1,3-dioxolane-2-yl)ethan-1-amine

ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

(2-(2-methyl-1,3-dioxolan-2-yl)ethyl)valine ethyl ester

(2-(2-methyl-1,3-dioxolan-2-yl)ethyl)valine ethyl ester

Conditions
ConditionsYield
With triethylamine In ethyl acetate; acetonitrile at 20℃;87.8%
With triethylamine In ethyl acetate; acetonitrile at 20℃;87.8%
2-(2-methyl-1,3-dioxolane-2-yl)ethan-1-amine
62240-37-3

2-(2-methyl-1,3-dioxolane-2-yl)ethan-1-amine

ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

(2-(2-methyl-1,3-dioxolane-2-yl)ethyl)valine ethyl ester

(2-(2-methyl-1,3-dioxolane-2-yl)ethyl)valine ethyl ester

Conditions
ConditionsYield
With triethylamine In acetonitrile at 20℃;87.8%
With triethylamine In acetonitrile at 20℃;87.8%
With triethylamine In acetonitrile at 20℃;87.8%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

2-butyl-1-[(3'-hydroxybiphenyl-4-yl)methyl]-4-spirocyclohexyl-1H-imidazol-5(4H)-one

2-butyl-1-[(3'-hydroxybiphenyl-4-yl)methyl]-4-spirocyclohexyl-1H-imidazol-5(4H)-one

2-butyl-1-[(3'-((1-ethoxycarbonyl-1-(1,1-dimethylmethyl)-methyl)oxy)biphenyl-4-yl)methyl]-4-spirocyclohexyl-1H-imidazol-5(4H)-one

2-butyl-1-[(3'-((1-ethoxycarbonyl-1-(1,1-dimethylmethyl)-methyl)oxy)biphenyl-4-yl)methyl]-4-spirocyclohexyl-1H-imidazol-5(4H)-one

Conditions
ConditionsYield
With potassium carbonate In acetonitrile Reflux;87.2%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

1-((1R,2S,4R,5S)-5-(tert-butyldiphenylsilyloxy)bicyclo[2.2.1]heptan-2-yl)thiourea
1191465-55-0

1-((1R,2S,4R,5S)-5-(tert-butyldiphenylsilyloxy)bicyclo[2.2.1]heptan-2-yl)thiourea

2-((1R,2S,4R,5S)-5-(tert-butyldiphenylsilyloxy)bicyclo[2.2.1]heptan-2-ylamino)-5-isopropylthiazol-4(5H)-one
1334758-82-5

2-((1R,2S,4R,5S)-5-(tert-butyldiphenylsilyloxy)bicyclo[2.2.1]heptan-2-ylamino)-5-isopropylthiazol-4(5H)-one

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In ethanol at 150℃; for 1h; Microwave irradiation;87%
1-benzofurane
271-89-6

1-benzofurane

ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

C15H18O3

C15H18O3

Conditions
ConditionsYield
With 2,4,6-trimethyl-pyridine; copper(l) iodide; tris[(2-pyridylmethyl)amine] In 1,4-dioxane at 110℃; for 48h;87%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

1-(methyl)-thiourea
598-52-7

1-(methyl)-thiourea

5-isopropyl-2-(methylamino)-1,3-thiazol-4(5H)-one

5-isopropyl-2-(methylamino)-1,3-thiazol-4(5H)-one

Conditions
ConditionsYield
With sodium methylate In methanol Reflux;86%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

2-Hydroxybenzophenone
117-99-7

2-Hydroxybenzophenone

2-(2-Benzoyl-phenoxy)-3-methyl-butyric acid ethyl ester

2-(2-Benzoyl-phenoxy)-3-methyl-butyric acid ethyl ester

Conditions
ConditionsYield
With potassium phosphate In dimethyl sulfoxide at 70℃; for 3h;82%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

p-nitrobenzenesulfonamide
6325-93-5

p-nitrobenzenesulfonamide

2-bromo-3-methyl-N-[(4-nitrophenyl)sulfonyl]butanamide

2-bromo-3-methyl-N-[(4-nitrophenyl)sulfonyl]butanamide

Conditions
ConditionsYield
Stage #1: ethyl 2-bromoisovalerate; p-nitrobenzenesulfonamide In toluene at 50℃; for 0.166667h; Sealed tube;
Stage #2: With titanium tetrachloride In toluene at 115℃; for 24h; Solvent; Sealed tube;
82%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

5-(1-(2-chlorobenzene)-5-methyl-1H-1,2,3-triazol-4-yl)-1,3,4-oxadiazole-2-mercaptan

5-(1-(2-chlorobenzene)-5-methyl-1H-1,2,3-triazol-4-yl)-1,3,4-oxadiazole-2-mercaptan

ethyl 2-(5-(1-(2-chlorobenzyl)-5-methyl-1H-1,2,3-triazol-4-yl)-1,3,4-oxadiazole-2-thioether)-3-methylbutyrate

ethyl 2-(5-(1-(2-chlorobenzyl)-5-methyl-1H-1,2,3-triazol-4-yl)-1,3,4-oxadiazole-2-thioether)-3-methylbutyrate

Conditions
ConditionsYield
With sodium hydroxide; monophenylthiourea In water; toluene at 80℃; for 5h;81.7%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

potassium ethyl xanthogenate
140-89-6

potassium ethyl xanthogenate

2-Ethoxythiocarbonylsulfanyl-3-methyl-butyric acid ethyl ester

2-Ethoxythiocarbonylsulfanyl-3-methyl-butyric acid ethyl ester

Conditions
ConditionsYield
In acetone 1.) 1 h, room temperature, 2.) 2 h, 50 deg C, 3.) overnight;81%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

dl-2-bromo-3-methyl-1-butanol
84984-06-5

dl-2-bromo-3-methyl-1-butanol

Conditions
ConditionsYield
With lithium aluminium tetrahydride In diethyl ether for 1h;80%
With lithium aluminium tetrahydride; diethyl ether
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

1-(3-phenylisoquinolin-1-yl)thiosemicarbazide
1214257-75-6

1-(3-phenylisoquinolin-1-yl)thiosemicarbazide

C28H32N4O3S
1214258-01-1

C28H32N4O3S

Conditions
ConditionsYield
With sodium acetate In ethanol for 8h; Reflux;80%
ethyl 2-bromoisovalerate
609-12-1

ethyl 2-bromoisovalerate

(4-fluorophenyl)(1H-pyrrol-2-yl)methanone
13169-73-8

(4-fluorophenyl)(1H-pyrrol-2-yl)methanone

ethyl 2-{2-[(4-fluorophenyl)carbonyl]-1H-pyrrol-1-yl}-3-methylbutanoate
1528751-84-9

ethyl 2-{2-[(4-fluorophenyl)carbonyl]-1H-pyrrol-1-yl}-3-methylbutanoate

Conditions
ConditionsYield
With caesium carbonate In acetonitrile at 20℃;80%

609-12-1Relevant academic research and scientific papers

Synthesis of α-alkylated γ-butyrolactones with concomitant anhydride kinetic resolution using a sulfamide-based catalyst

Claveau, Romain,Twamley, Brendan,Connon, Stephen J.

supporting information, p. 7574 - 7578 (2018/11/02)

The Kinetic Resolution (KR) of α-alkylated enolisable disubstituted anhydrides has been shown to be possible for the first time. In the presence of an ad hoc designed novel class of bifunctional sulfamide organocatalyst, a regio-, diastereo- and enantioselective cycloaddition reaction between the enolisable anhydride and benzaldehydes provides densely functionalised γ-butyrolactones in one pot (up to 19:1 dr, 94% ee) with control over three contiguous stereocentres. The concomitant resolution of the starting material anhydride, provides access to a range of chiral succinate derivatives with selectivity factors up to S? = 10.5.

CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

-

Page/Page column 42, (2010/11/28)

An object of the present invention is to provide novel carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof having an excellent adipose tissue weight reducing effect, hypoglycemic effect, and hypolipidemic effect, which are useful as a preventive and/or therapeutic agent for fatty liver, obesity, lipid metabolism abnormality, visceral adiposity, diabetes, hyperlipemia, impaired glucose tolerance, hypertension, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and the like. The above-mentioned object can be achieved by carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof, wherein the carbazole derivatives are represented by the following general formula (I): (In the formula (I), the ring A represents phenyl group or the like; X represents -O- or the like; Y represents =N- or the like; a and b represent methylene group or the like; both V and Z represent -O- or the like; W represents a C1-C10 alkylene group whose 1 or 2 hydrogen atoms may be substituted by a phenyl group or a C1-C6 alkyl group; 1,2-phenylene group; 1,3-cyclohexyl group; or the like; R1 represents methyl group or the like; R2 represents methoxy group or the like; and R3 represents carboxy group or the like.)

Pyrimidine acyclonucleoside derivatives, preparation method and use thereof

-

Page/Page column 15-16, (2010/02/12)

The invention relates to a compound having general formula (I): wherein n is equal to 3; R1 is an ethyl or isopropyl group; each of the R2 groups is independently of each other a hydrogen atom, a C1-C3 alkyl group or a halogen atom; one of the R3 and R4 groups represents a hydrogen atom while the other of the R3 and R4 groups represents an OH or OR5 group, where R5 can be a C2-C7 acyl group, an alkyl(C1-C6)animo-carbonyl group, an aralkyl(C1-C6)aminocarbonyl optionally substituted on the aryl, an arylcarbonyl group optionally substituted or a heteroarylaminocarbonyl group. Said compound is particularly suitable as an antiviral agent and especially as an anti-HIV-1 agent.

Syntheses based on monocarbon molecules: II. Synthesis of ethyl isovalerate by isobutene carbonylation with carbon monoxide and ethanol in the presence of phosphine palladium complexes. Ethyl α-bromoisovalerate

Suerbaev,Abyzbekova,Shalmagambetov,Zhubanov

, p. 516 - 517 (2007/10/03)

Optimal conditions for the synthesis of ethyl isovalerate by isobutene hydrocarbalkoxylation with carbon monoxide and ethanol in the presence of the catalytic system PdCl2(PPh3)2 + PPh3 + p-TsOH were found. Bromination of ethyl isovalerate under conditions of the Hell-Volgard-Zelinskii reaction gave ethyl α-bromoisovalerate which is the main active component in korvalol medicine.

Direct gaschromatographic separation of drug racemates

Schleuder,Duerrbeck,Jira

, p. 381 - 386 (2007/10/03)

For inspection of the direct separability of synthetic drug racemates through GC/MS a uniform scheme is proposed and checked with 35 drugs and two cyclodextrin capillary columns. All investigated analytes vaporized without decomposition, 26 of them are separable in the enantiomers, among them 10 with separation to the baseline and 14 with CO-NH-structure.

The Development of Cyclic Sulfolanes as Novel and High-Affinity P2 Ligands for HIV-1 Protease Inhibitors

Ghosh, Arun K.,Lee, Hee Yoon,Thompson, Wayne J.,Culberson, Chris,Holloway, M. Katharine,et al.

, p. 1177 - 1188 (2007/10/02)

Design and synthesis of a novel series of protease inhibitors incorporating conformationally constrained cyclic ligands for the S2-substrate binding site of HIV-1 protease is described. We recently reported urethanes of 3-tetrahydrofuranyl as P2 ligands for HIV-1 protease inhibitors. Subsequently, we have found that the urethane of 3(S)-hydroxysulfolane further increased the in vitro potency of these inhibitors. Furthermore, introduction of a small 2-alkyl group cis to the 3-hydroxyl group of either heterocyclic system further enhanced enzyme affinity. The cis-2-isopropyl group thus far offered optimum enhancement of the inhibitory properties. This led to the discovery of inhibitor 43 (IC50 3.5 nM, CIC95 50+/-14 nM) of comparable in vitro antiviral potency to the current clinical candidate 1 (Ro 31-8959) but of reduced molecular weight due to the exclusion of the P3 quinoline ligand. Also, it has been demonstrated that the octahydropyrindene derivative 34 is an effective replacement of the P1' decahydroisoquinoline derivative.

Preparation of substituted alpha-halogeno-propionic acids and their derivatives

-

, (2008/06/13)

Substituted α-halogenopropionic acids and their derivatives of the general formula STR1 wherein R1 to R3, Y and X have the meanings given in the description, are prepared by a process which is characterized in that substituted vinylidene chlorides of the general formula STR2 are reacted with chlorine or bromine chloride in the presence of compounds of the formula wherein R5 and R6 have the meaning given in the description, and the products obtained are treated, if appropriate, with water or alcohol. Certain of the substituted α-halogeno-propionic acids and the substituted vinylidene chloride of the formula STR3 are new. The end products are useful as herbicides and intermediates for insecticides.

Unnatural nucleosides and nucleotides. III. Preparation of 2-14C and 4-14C labelled 5-alkyluracils and 5-alkyl-2'-deoxyuridines

Szabolcs,Kruppa,Sagi,Otvos

, p. 713 - 726 (2007/10/08)

2-14C Labelled 5-alkyluracils were prepared by condensation of the diethylacetals of α-formyl-carbonic acid esters with 14C-thiourea. Compounds labelled at 4-C were synthesized by condensation of the labelled carboxylic acid derivatives with thiourea. β-Anomers of 5-alkyl-2'-deoxyuridines were obtained in a fairly good radiochemical yield. Alkyl substituents ranged from methyl to tetradecyl, isopropyl and tert-butyl.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 609-12-1